Rapid Micro Biosystems, Inc. (RPID)
| Market Cap | 111.44M |
| Revenue (ttm) | 33.59M |
| Net Income (ttm) | -47.12M |
| Shares Out | 45.77M |
| EPS (ttm) | -1.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 140,699 |
| Open | 2.410 |
| Previous Close | 2.360 |
| Day's Range | 2.410 - 2.489 |
| 52-Week Range | 2.010 - 4.940 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 8.00 (+228.54%) |
| Earnings Date | May 8, 2026 |
About RPID
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biologics, medical devices, and personal care products in the United States, Switzerland, Germany, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the antiquat... [Read more]
Financial Performance
In 2025, Rapid Micro Biosystems's revenue was $33.59 million, an increase of 19.74% compared to the previous year's $28.05 million. Losses were -$47.12 million, 0.50% more than in 2024.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for RPID stock is "Strong Buy" and the 12-month stock price target is $8.0.
News
Rapid Micro Biosystems Transcript: 2026 KeyBanc Capital Markets Healthcare Forum
Automation of microbial quality control is driving faster, more reliable pharmaceutical manufacturing, with strong recurring revenue from consumables and services. 2026 guidance targets 16% revenue growth, margin expansion, and significant runway for customer and market penetration, supported by strategic partnerships and operational efficiencies.
Rapid Micro Biosystems Earnings Call Transcript: Q4 2025
Q4 revenue grew 37% year-over-year to $11.3M, driven by record system placements and strong consumable growth. 2026 guidance calls for $37–$41M revenue, 30–38 system placements, and gross margin expansion to ~20%, supported by cost reductions and new product innovation.
Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance
Reports record fourth quarter 2025 total revenue of $11.3 million , representing 37% growth compared to fourth quarter 2024 Reports full year 2025 total revenue of $33.6 million , representing 20% gr...
Rapid Micro Biosystems Announces Follow-on Multi-System Order from Samsung Biologics to Expand Deployment of Growth Direct® Platform
Companies deepen partnership to advance automated, integrated microbiology quality control Companies deepen partnership to advance automated, integrated microbiology quality control
Rapid Micro Biosystems to Participate in KeyBanc Capital Markets Healthcare Forum
LEXINGTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation s...
Rapid Micro Biosystems Transcript: TD Cowen 46th Annual Health Care Conference
Rapid automation of pharmaceutical microbial quality control is driving strong recurring revenue and margin growth, supported by global expansion and a strategic partnership with MilliporeSigma. AI-driven data insights and regulatory trends are expected to accelerate adoption, with significant impact projected from 2026 onward.
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems to Announce Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
LEXINGTON, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation so...
Rapid Micro Biosystems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rapid automation of pharmaceutical microbial quality control is driving strong recurring revenue and margin expansion, supported by global adoption, a robust land-and-expand strategy, and a growing partnership with MilliporeSigma. Continued innovation and operational efficiency position the business for further growth and break-even in the near term.
Rapid Micro Biosystems Announces Record Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
LEXINGTON, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems to Present at 44th Annual J.P. Morgan Healthcare Conference
LEXINGTON, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems Transcript: Stifel 2025 Healthcare Conference
Growth Direct's automation is driving faster, more accurate microbial quality control, with expanding adoption among top pharma companies and increasing multi-system orders. The MilliporeSigma partnership is set to boost global reach and margins, while ongoing efficiency initiatives and incremental investments support a positive margin outlook and sustained 20% revenue growth.
Rapid Micro Biosystems Earnings Call Transcript: Q3 2025
Q3 revenue grew 3% to $7.8M, driven by record consumable sales and strong recurring revenue. A record multi-system order and MilliporeSigma collaboration are set to boost 2026 growth and margins. Full-year revenue guidance was raised to at least $33M.
Rapid Micro Biosystems Reports Third Quarter 2025 Financial Results; Announces Record Multi-System Customer Order and Raises Full-Year Revenue and System Placement Guidance
LEXINGTON, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference
LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems to Announce Third Quarter 2025 Financial Results on November 7, 2025
LEXINGTON, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation so...
Trinity Capital Inc. Provides $45 Million in Growth Capital to Rapid Micro Biosystems, Modernizing Healthcare Industry Practices
PHOENIX , Sept. 22, 2025 /PRNewswire/ -- Trinity Capital Inc. (Nasdaq: TRIN) (the "Company"), a leading alternative asset manager, today announced the commitment of $45 million in growth capital to Ra...
Rapid Micro Biosystems Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Rapid Micro Biosystems is driving automation in microbial quality control, achieving strong revenue growth and expanding its global footprint, especially through a strategic partnership with Merck. The company targets 25–30% annual growth and aims for 50% gross margins by 2027.
Rapid Micro Biosystems to Present at the H.C. Wainwright 27th Annual Global Investment Conference
LEXINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation s...
Rapid Micro Biosystems Earnings Call Transcript: Q2 2025
Q2 2025 revenue rose 10% year-over-year to $7.3M, with recurring revenue up 15% and gross margin improving to 4%. A new $45M term loan was secured, and full-year guidance was reaffirmed, though system placements are expected at the low end due to trade uncertainties.
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation so...
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission criti...
Rapid Micro Biosystems to Announce Second Quarter 2025 Financial Results on August 12, 2025
LEXINGTON, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation so...
Rapid Micro Biosystems Announces Appointment of Dr. Dafni Bika to Board of Directors
LEXINGTON, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critic...